Compare Innovative Industrial Properties Inc (IIPR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Viatris Inc — how do they compare? Innovative Industrial Properties Inc trades at $58.2 (market cap $1.67B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 11.2× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (13.18%). Which is the better fit depends on your goals.
| IIPR | VTRS | |
|---|---|---|
Market Cap | $1.67B | $18.69B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $17.86 |
52-Week Low | $44.58 | $9.49 |
Enterprise Value | $2.21B | $30.80B |
Dividend Yield | 13.18% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $57.69, showing modest daily gains of 0.37%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a P/E of 13.05 and net margin of 52.27%. Recent Q2 2026 earnings beat expectations with $1.36 EPS versus $1.02 forecast. The company maintains robust cash flow from operations at $198.19M and recently declared a $1.90 dividend for H1-2026.
Outlook remains cautiously optimistic despite technical weakness. The 9.09% dividend yield and attractive valuation metrics provide support, but declining revenue from $266M (2025) to $264M (2026) and tenant concentration risks in the cannabis REIT sector warrant monitoring. Analyst consensus leans Hold (54.55%) with institutional interest growing.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
